 Lymphoma, Mantle-Cell
"Lymphoma, Mantle-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
| Descriptor ID |
D020522
|
| MeSH Number(s) |
C04.557.386.480.525 C15.604.515.569.480.525 C20.683.515.761.480.525
|
| Concept/Terms |
Lymphoma, Mantle-Cell- Lymphoma, Mantle-Cell
- Lymphoma, Mantle Cell
- Lymphomas, Mantle-Cell
- Mantle-Cell Lymphomas
- Mantle-Zone Lymphoma
- Lymphoma, Mantle-Zone
- Lymphomas, Mantle-Zone
- Mantle Zone Lymphoma
- Mantle-Zone Lymphomas
- Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
- Diffuse Lymphocytic Lymphoma, Poorly Differentiated
- Lymphoma, Small-Cell, Centrocytic
- Lymphocytic Lymphoma, Diffuse, Poorly-Differentiated
- Lymphoma, Centrocytic Small-Cell
- Centrocytic Small-Cell Lymphoma
- Centrocytic Small-Cell Lymphomas
- Lymphoma, Centrocytic Small Cell
- Lymphomas, Centrocytic Small-Cell
- Small-Cell Lymphoma, Centrocytic
- Small-Cell Lymphomas, Centrocytic
- Lymphoma, Lymphocytic, Diffuse, Intermediate Differentiated
- Lymphoma, Lymphocytic, Diffuse, Poorly-Differentiated
- Mantle-Cell Lymphoma
- Mantle Cell Lymphoma
- Lymphocytic Lymphoma, Diffuse, Poorly Differentiated
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Mantle-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Mantle-Cell".
This graph shows the total number of publications written about "Lymphoma, Mantle-Cell" by people in UAMS Profiles by year, and whether "Lymphoma, Mantle-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 1 | 1 | | 2023 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 | | 2020 | 2 | 0 | 2 | | 2019 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2009 | 1 | 1 | 2 | | 2006 | 1 | 0 | 1 | | 2005 | 2 | 0 | 2 | | 2003 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphoma, Mantle-Cell" by people in Profiles over the past ten years.
-
Hamilton MP, Craig E, Gentille Sanchez C, Mina A, Tamaresis J, Kirmani N, Ehlinger Z, Syal S, Good Z, Sworder B, Schroers-Martin J, Lu Y, Muffly L, Negrin RS, Arai S, Lowsky R, Meyer E, Rezvani AR, Shizuru J, Weng WK, Shiraz P, Sidana S, Bharadwaj S, Smith M, Dahiya S, Sahaf B, Kurtz DM, Mackall CL, Tibshirani R, Alizadeh AA, Frank MJ, Miklos DB. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Adv. 2024 Jun 25; 8(12):3314-3326.
-
Kiguchi T, Hiramatsu Y, Ota S, Uchiyama M, Matsuo M, Okamura M, Morimoto S, Tanizawa Y, Tajimi M, Payakachat N. Patient perspectives on treatment for mantle cell lymphoma and chronic lymphocytic leukemia in Japan. J Clin Exp Hematop. 2024 Jun 27; 64(2):119-128.
-
Markowitz JT, Mazerolle F, Lovell T, Hess LM, Abada PB, Regnault A, Payakachat N. Mixed-methods research to support the use of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library. J Patient Rep Outcomes. 2024 Jan 22; 8(1):8.
-
Pina-Oviedo S, Motwani P. Composite ALK-negative anaplastic large-cell lymphoma and mantle cell lymphoma. Blood. 2023 02 02; 141(5):556.
-
Shah DS, Homer NA, Epstein A, Durairaj VD. Simultaneous presentation of orbital mantle cell lymphoma and endocrine mucin-producing sweat gland carcinoma. Orbit. 2022 Aug; 41(4):509-513.
-
Kamel MG, El-Qushayri AE, Sayed AK, Huy NT. Using the primary site as a prognostic tool for nodal mantle cell lymphoma: a SEER-based study. J Comp Eff Res. 2020 08; 9(12):861-876.
-
Zhou X, Steinhardt MJ, D?ll J, Krummenast F, Danhof S, Meckel K, Nickel K, Grathwohl D, Leicht HB, Rosenwald A, Einsele H, Rasche L, Kort?m M. Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma. Eur J Haematol. 2020 Apr; 104(4):352-355.
-
Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, Haun R, Lan R, Mackintosh SG, Mao X, Song X, Zhang J, Pham LV, Lorenzi PL, Marszalek J, Heffernan T, Draetta G, Jones P, Futreal A, Nomie K, Wang L, Wang M. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019 05 08; 11(491).
-
Gelman A, Valdes-Rodriguez R, Bhattacharyya S, Yosipovitch G. A case of primary cutaneous mucormycosis caused by minor trauma. Dermatol Online J. 2015 Jan 15; 21(1).
|
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|